Antitumor Agents 270. Novel Substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one Derivatives As Potent and Highly Selective Anti-breast Cancer Agents

Overview

Journal Bioorg Med Chem

Specialties Biochemistry
Chemistry

Date 2009 Dec 26

PMID 20034799

Citations 6

Authors

Yizhou Dong

Qian Shi

Kyoko Nakagawa-Goto

Pei-Chi Wu

Susan L Morris-Natschke

Arnold Brossi

Kenneth F Bastow

Jing-Yu Lang

Mien-Chie Hung

Kuo-Hsiung Lee

Affiliations

Soon will be listed here.

Abstract

6-Phenyl-4H-furo[3,2-c]pyran-4-one derivatives based on neo-tashinlactone (1) were synthesized and evaluated as novel anti-breast cancer agents. Compounds 10-13, 23, 25, and 27 showed potent inhibition against the SK-BR-3 breast cancer cell line. Importantly, 25 and 27 showed the highest cancer cell line selectivity, being approximately 100-250-fold more potent against SK-BR-3 (ED(50) 0.28 and 0.44microM, respectively) compared with other cancer cell lines tested. In addition, 25 displayed low cytotoxicity against normal breast cell lines 184A1 and MCF10A. Compounds 25 and 27 merit further investigation in our continuing program to generate and develop selective anti-breast cancer agents.

Citing Articles

Synthesis of new condensed naphthoquinone, pyran and pyrimidine furancarboxylates.

Gomonov K, Pelipko V, Litvinov I, Pilipenko I, Stepanova A, Lapatin N Beilstein J Org Chem. 2025; 21:340-347.

PMID: 39968289 PMC: 11833173. DOI: 10.3762/bjoc.21.24.

Anti-proliferative, Morphological and Molecular Docking Studies of New Thiophene Derivatives and their Strategy in Ionic Liquids Immobilized Reactions.

Mohareb R, Mukhtar S, Parveen H, Abdelaziz M, Alwan E Anticancer Agents Med Chem. 2024; 24(9):691-708.

PMID: 38321904 DOI: 10.2174/0118715206262307231122104748.

Recent Progress of Research on Herbal Products Used in Traditional Chinese Medicine: the Herbs belonging to The Divine Husbandman's Herbal Foundation Canon ( Shén Nóng Běn Cǎo Jīng).

Lee K, Morris-Natschke S, Qian K, Dong Y, Yang X, Zhou T J Tradit Complement Med. 2014; 2(1):6-26.

PMID: 24716110 PMC: 3943012. DOI: 10.1016/s2225-4110(16)30066-9.

In vitro cytotoxic potential of newly synthesized furo[3,2-c]pyran-4-one derivatives in cultured human lymphocytes.

Eroglu H, Koca I, Yildirim I Cytotechnology. 2011; 63(4):407-13.

PMID: 21573773 PMC: 3140834. DOI: 10.1007/s10616-011-9358-5.

Antitumor agents 287. Substituted 4-amino-2H-pyran-2-one (APO) analogs reveal a new scaffold from neo-tanshinlactone with in vitro anticancer activity.

Dong Y, Nakagawa-Goto K, Lai C, Morris-Natschke S, Bastow K, Lee K Bioorg Med Chem Lett. 2011; 21(8):2341-4.

PMID: 21420855 PMC: 3072684. DOI: 10.1016/j.bmcl.2011.02.084.

References

Chari R . Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2007; 41(1):98-107. DOI: 10.1021/ar700108g. View

Wang X, Nakagawa-Goto K, Bastow K, Don M, Lin Y, Wu T . Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. J Med Chem. 2006; 49(18):5631-4. DOI: 10.1021/jm060184d. View

Raghavan B, Balasubramanian R, Steele J, Sackett D, Fecik R . Cytotoxic simplified tubulysin analogues. J Med Chem. 2008; 51(6):1530-3. DOI: 10.1021/jm701321p. View

Coley H . Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008; 34(4):378-90. DOI: 10.1016/j.ctrv.2008.01.007. View

Wang X, Bastow K, Sun C, Lin Y, Yu H, Don M . Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J Med Chem. 2004; 47(23):5816-9. DOI: 10.1021/jm040112r. View

Magedov I, Manpadi M, Ogasawara M, Dhawan A, Rogelj S, Van Slambrouck S . Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones. J Med Chem. 2008; 51(8):2561-70. PMC: 3125133. DOI: 10.1021/jm701499n. View

Balunas M, Kinghorn A . Drug discovery from medicinal plants. Life Sci. 2005; 78(5):431-41. DOI: 10.1016/j.lfs.2005.09.012. View

Dong Y, Shi Q, Liu Y, Wang X, Bastow K, Lee K . Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents. J Med Chem. 2009; 52(11):3586-90. PMC: 2754228. DOI: 10.1021/jm9001567. View

Boeckman Jr R, Ge P, Reed J . New heterocyclic precursors for thermal generation of reactive, electron-rich 1,2-diaza-1,3-butadienes. Org Lett. 2001; 3(23):3647-50. DOI: 10.1021/ol0165645. View

10.

Vuorelaa P, Leinonenb M, Saikkuc P, Tammelaa P, Rauhad J, Wennberge T . Natural products in the process of finding new drug candidates. Curr Med Chem. 2004; 11(11):1375-89. DOI: 10.2174/0929867043365116. View

11.

Saklani A, Kutty S . Plant-derived compounds in clinical trials. Drug Discov Today. 2008; 13(3-4):161-71. DOI: 10.1016/j.drudis.2007.10.010. View

12.

Hariprakasha H, Kosakowska-Cholody T, Meyer C, Cholody W, Stinson S, Tarasova N . Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502). J Med Chem. 2007; 50(23):5557-60. DOI: 10.1021/jm7009777. View

13.

Hickey J, Ruhayel R, Barnard P, Baker M, Berners-Price S, Filipovska A . Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J Am Chem Soc. 2008; 130(38):12570-1. DOI: 10.1021/ja804027j. View

14.

Albrand G, Terret C . Early breast cancer in the elderly: assessment and management considerations. Drugs Aging. 2008; 25(1):35-45. DOI: 10.2165/00002512-200825010-00004. View

15.

Pedram B, van Oeveren A, Mais D, Marschke K, Verbost P, Groen M . A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline. J Med Chem. 2008; 51(13):3696-9. DOI: 10.1021/jm8004256. View